Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. - Test2 - elhamkhani - TriplyDB

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

http://www.wikidata.org/entity/Q27852806

about

Crizotinib: from discovery to accelerated development to front-line treatment Targeted therapies and immunotherapy in non-small-cell lung cancer Tackling ALK in non-small cell lung cancer: the role of novel inhibitors Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer Withdrawal of anticancer therapy in advanced disease: a systematic literature review Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application CIViC database Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Ceritinib: A primer for pharmacists.Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment Novel agents in development for advanced non-small cell lung cancer.Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007).Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy.Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution.Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer.Update on systemic therapy of advanced non-small-cell lung cancer.Management of NSCLC: focus on crizotinib.New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC.Alectinib for treatment of ALK-positive non-small-cell lung cancer.Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.ALK alterations and inhibition in lung cancer.

P2860

6e52ddf58c3c2cc9dfd4f07814218e2274aeab88

P248

Q26738385-C19C9A44-26CD-4080-BB08-AC3A10D93D4B Q26738986-1792431D-A289-44CD-B883-C7FE11850D33 Q26740329-77C4085D-EE14-44F4-81D4-76104A635427 Q26745427-1AD46071-A4D8-4019-9D0B-806A0F68EBEC Q26777486-9902C480-ED20-4FBE-8F6E-CC3262FF2521 Q26795555-3BF482A5-F27C-46FF-B705-7B95C05467A1 Q26795556-0BD52123-1B65-4195-8DF3-56C4E0DD1E36 Q27612411-C11F04C8-1074-45C8-890A-0967837C334D Q27853360-5BFFA781-C9E0-4414-952D-BCAC90357F29 Q30244613-5BCC6C69-7E84-4A99-B312-72E246D70138 Q33567889-C2992B9C-7EA6-4C5C-B791-D7407065D799 Q33591738-522B9DEE-F57E-4A34-8F64-BADE5FE62749 Q34127899-36B6DE77-5B04-448B-B012-14F7EF7A07E6 Q34389263-D23165C4-4F8C-46F3-BB59-55CDB996AA7A Q34564071-25018490-1C96-47D4-B706-060FE2938A58 Q35057308-800EC31E-40E7-42D6-9EC3-853764726B52 Q35549714-1333D55F-5952-4F3E-BBA3-81CDA90F8935 Q35909271-62B7F346-8253-4C71-BA06-08117AB82C98 Q35918612-D3EAE7CB-C3BE-4364-A094-0E895C57951B Q36322851-9C477F0F-7E84-4280-BA2F-846AE432E727 Q36594257-78DCA247-73ED-45A5-9606-FA8D51E8B2FB Q36797256-DF8C70EC-7867-479B-BCA5-0816F2B7C417 Q37045504-B9F7E677-36DC-4061-ADAF-B0F8CD664F7C Q37350770-7BF44A1C-02E6-4A52-AAEF-3981E94B1715 Q37462477-AC155B1F-1167-409C-B28F-7219C3E09282 Q37649196-2F306971-D590-46C8-B3AE-5FDB482FB86E Q37662206-98B8E769-6CF1-4E20-835C-268BC99BA9BC Q37737536-685C2BDE-7CC7-4904-9797-17C9D27019B2 Q38237463-1D65065F-CB7A-487F-85CA-EFF0239827C3 Q38258633-8575C52A-A37C-4D4A-86C7-BF8ADA50ED32 Q38576015-8C2636B5-72C3-47EB-8469-A8C284192A7B Q38631019-10BA2226-864A-4FBD-A53A-1C3B64A99D64 Q38669285-33DC933D-2954-4F48-BF6A-8CD61E36478C Q38739807-579710E3-39D5-430B-908A-839A9C854954 Q38746336-C6127E35-CF37-4F6C-9F7E-D7CF1943C68F Q38748356-E138C61C-74F1-4344-A0C0-59F2C1FCBB74 Q38763108-E2183FE8-A534-41AA-9E67-359DB8BF66ED Q38805618-9A688814-23CA-4797-A558-66F265A2C865 Q38816700-575D91B2-6704-40FB-A03F-E101539FA838 Q38820412-8406544E-4AEC-43E7-9F06-78A0A1A083A8

P2860

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

http://www.wikidata.org/entity/Q27852806

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.

@ast

Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.

@en

Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.

@nl

type

label

Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.

@ast

Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.

@en

Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.

@nl

prefLabel

Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.

@ast

Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.

@en

Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.

@nl

P1433

Q27852806-E42C85F2-345B-4A44-A743-67167F268493

P1476

Q27852806-38E73F5F-229F-47D9-911F-EBA672AED2F6

P2093

Q27852806-232AF0CC-ACFE-4EDD-BE43-37A1AFF5DAE1

Q27852806-2AB2D2D5-BE9F-468F-910E-842F8903E8FC

Q27852806-31B7754A-011B-43F6-A15A-4FD3E4B49B6A

Q27852806-5BA05771-D22E-4C51-82DE-496405CE30EC

Q27852806-6ACAED64-347D-4674-B33E-DB4023A11524

Q27852806-72A00B9A-DB98-42E1-9962-04E6C67C5408

Q27852806-76D9B096-2C1C-4267-86B8-689498F692B6

Q27852806-9D265E0D-3A03-4A89-8A4F-C9C37BAE167F

Q27852806-D727DC41-2489-4C3F-96EF-92EF6E8465C7

Q27852806-EB8A4935-904D-4A45-9D78-E668DDD59E52

P2860

Q27852806-0D5B60C2-19E6-4E0B-8482-E3AC53E5AB87

Q27852806-20C2B166-6FEE-4350-A9C1-749C6D34B19B

Q27852806-27A0699D-0218-44BA-8163-8BE56E4EBB8E

Q27852806-2AE8AF03-A8C5-4921-BE86-89D47421FF41

Q27852806-2FB875F6-4779-4C30-A8DC-D0FB8D3957CF

Q27852806-4987F565-7465-4A15-8513-E07D03FA4979

Q27852806-4E470719-F0D3-47DF-896B-C8916FDF2086

Q27852806-5ECD94AD-5EC7-46A4-B770-E8442E2B29B6

Q27852806-604D19B8-089A-4120-90DA-297DD71DF52F

Q27852806-6B0BC43A-8513-4101-9943-828B9BAA2E10

P304

Q27852806-30ED2164-76E3-4FBA-A32E-DCB7A3365352

P31

Q27852806-BA59A0E0-0058-4C47-86A2-443A624F886B

P3181

Q27852806-076927B9-E1A9-42D7-B9D1-D445FCE839EC

P356

Q27852806-9E58A070-533F-4775-AE7E-D6BF77DF6827

P433

Q27852806-42289D46-2819-4CF5-A576-4C9E29438B14

P478

Q27852806-612B071F-25BD-47DB-85C7-47C437D3052A

P577

Q27852806-5AF92CFE-4A60-48D0-BA39-7EC9D03715B6

P5875

Q27852806-FB025A02-A77F-4B56-A775-7D0C4B86D3B2

P698

Q27852806-716B0EB4-CBC0-423A-A29F-9982E9CC01E3

P921

Q27852806-385AE339-39C3-4B39-9087-EE6896496133

P3181

P356

P1433

Annals of Oncology

P1476

Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.

@en

P2093

C H Bartlett

http://www.w3.org/2001/XMLSchema#string

D P Cohen

http://www.w3.org/2001/XMLSchema#string

D-W Kim

http://www.w3.org/2001/XMLSchema#string

G A Otterson

http://www.w3.org/2001/XMLSchema#string

G J Riely

http://www.w3.org/2001/XMLSchema#string

J W Clark

http://www.w3.org/2001/XMLSchema#string

L Crinò

http://www.w3.org/2001/XMLSchema#string

P A Jänne

http://www.w3.org/2001/XMLSchema#string

P Selaru

http://www.w3.org/2001/XMLSchema#string

S-H I Ou

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

P304

415-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

559999

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/ANNONC/MDT572

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259985993

http://www.w3.org/2001/XMLSchema#string

P698

24478318

http://www.w3.org/2001/XMLSchema#string

P921